Inotiv, Inc. will release fiscal 2025 Q4 and full year results on December 3, 2025, followed by a conference call.
Quiver AI Summary
Inotiv, Inc. announced that it will release its financial results for the fourth quarter and full year of fiscal 2025, which ended on September 30, 2025, on December 3, 2025, after the stock market closes. Following the announcement, the company will host a conference call at 4:30 p.m. ET to discuss the results, with participation details provided. A live webcast of the call will be available on the company's website, along with a replay for those unable to attend. Inotiv specializes in nonclinical and analytical drug discovery and development services, aiming to improve the efficiency and cost-effectiveness of bringing new drugs and medical devices to market. The release also includes mentions of potential risks and uncertainties related to the company's cybersecurity incident and compliance with legal agreements.
Potential Positives
- The announcement of the financial results and the scheduled conference call demonstrate the company's commitment to transparency and communication with investors.
- Inotiv’s dedication to improving efficiency and reducing costs in drug development may position the company favorably in the competitive contract research organization market.
- The conference call offers an opportunity for stakeholders to gain insights into the company's performance and future plans, which could bolster investor confidence.
Potential Negatives
- The company is facing ongoing risks and uncertainties related to a cybersecurity incident, which may negatively impact its operations and reputation.
- There are potential compliance issues related to the U.S. Department of Justice's Resolution and Plea Agreements, which could lead to financial and operational challenges.
- Impacts of current and future claims and litigation could pose significant risks to the company's financial stability and public perception.
FAQ
When will Inotiv announce its fiscal 2025 financial results?
Inotiv will announce its fiscal 2025 fourth quarter and full year financial results on December 3, 2025.
What time is the financial results conference call?
The conference call to discuss the financial results will be held at 4:30 p.m. Eastern Time on December 3, 2025.
How can I participate in the Inotiv conference call?
Interested parties can join the call by dialing 1-800-225-9448 (Domestic) or 1-203-518-9708 (International).
Where can I find the live webcast of the conference call?
The live conference call webcast can be accessed in the Investors section of Inotiv's website or via a specific link provided in the release.
Is there a replay available for the conference call?
Yes, an online replay of the conference call will be available in the Investors section of Inotiv's website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NOTV Insider Trading Activity
$NOTV insiders have traded $NOTV stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $NOTV stock by insiders over the last 6 months:
- R MATTHEW NEFF has made 0 purchases and 6 sales selling 12,000 shares for an estimated $21,367.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NOTV Hedge Fund Activity
We have seen 32 institutional investors add shares of $NOTV stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KENNEDY CAPITAL MANAGEMENT LLC removed 1,003,801 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,826,917
- BALYASNY ASSET MANAGEMENT L.P. removed 668,912 shares (-40.4%) from their portfolio in Q3 2025, for an estimated $969,922
- MILLENNIUM MANAGEMENT LLC removed 276,705 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $401,222
- GSA CAPITAL PARTNERS LLP added 234,518 shares (+inf%) to their portfolio in Q3 2025, for an estimated $340,051
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 234,120 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $339,474
- THURSTON, SPRINGER, MILLER, HERD & TITAK, INC. removed 177,725 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $257,701
- EHP FUNDS INC. added 148,521 shares (+inf%) to their portfolio in Q3 2025, for an estimated $215,355
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WEST LAFAYETTE, Ind., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”) , a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 fourth quarter and full year ended September 30, 2025, on Wednesday, December 3, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results.
Interested parties may participate in the call by dialing:
- 1-800-225-9448 (Domestic)
- 1-203-518-9708 (International)
-
INOTIV (Conference ID)
The live conference call webcast will be accessible in the Investors section of the Company’s web site and directly via the following link:
https://viavid.webcasts.com/starthere.jsp?ei=1743648&tp_key=169e7235ab
For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv’s web site at: https://ir.inotiv.com/events-and-presentations/default.aspx .
About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here:
https://www.inotiv.com/
.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the Company's assessment of its cybersecurity incident, ongoing or potential impacts, and efforts of the Company related to the incident, the Company’s ability to comply with covenants under its credit agreement, compliance with the Resolution and Plea Agreements with the U.S. Department of Justice and the expected impacts on the Company related to the compliance plan, compliance monitor, and the expected financial commitments, changes in the market and demand for the Company’s products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, claims and litigation against or involving the Company, its business and/or its industry, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
| Company Contact | Investor Relations | |
| Inotiv, Inc. | LifeSci Advisors | |
| Beth A. Taylor, Chief Financial Officer | Steve Halper | |
| (765) 497-8381 | (646) 876-6455 | |
| [email protected] | [email protected] |
